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Microglial cells in brain and spinal cord are characterized by high expression
of the chemokine receptor CX3CR1. Expression of the sole CX3CR1 ligand, the
membrane-tethered and sheddable chemokine CX3CL1/fractalkine, is restricted in the
brain parenchyma to selected neurons. Here we summarize our current understanding
of the physiological role of CX3CR1 for microglia function and the CX3C axis in
microglial/neuronal crosstalk in homeostasis and under challenge. Moreover, we will
discuss the efforts of our laboratory and others to exploit CX3CR1 promoter activity for the
visualization and genetic manipulation of microglia to probe their functional contributions
in the central nerve system (CNS) context.
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INTRODUCTION
Microglia are members of the mononuclear phagocyte system
alongside other macrophages, monocytes and dendritic cells
(Geissmann et al., 2010). Sequestered behind the blood brain bar-
rier (BBB) in the unique neuronal/macroglial context, microglia
display a gene expression profile that significantly differs from
other tissue macrophages (Gautier et al., 2012). Moreover, high-
lighting its independence the microglia compartment is estab-
lished well before birth from a primitive hematopoietic wave
and subsequently maintains itself throughout adulthood through
longevity and limited self-renewal (Alliot et al., 1999; Ginhoux
et al., 2010). Microglia share this prenatal establishment with
other tissue macrophage populations; however the latter seem
less secluded and more promiscuous with respect to the incorpo-
ration of monocytic cells derived from the fetal liver or during
challenge (Hoeffel et al., 2012; Yona et al., 2013). In contrast,
even after a prominent trauma-associated influx of monocytes
into the injured central nerve system (CNS), these cells do not
seem to permanently seed the brain. Rather, the steady state
relying solely on microglia seems to be restored (Ajami et al.,
2011). Steady state microglia are distributed throughout the CNS,
including brain and spinal cord, although there is evidence for
considerable region specific differences in density, phenotype and
responsiveness (de Haas et al., 2008). As immune cells, microglia
are sensors of injury and pathologic conditions (Hanisch and
Kettenmann, 2007). More recent data have furthermore revealed
critical microglia contributions during CNS development and
brain homeostasis (Tremblay et al., 2011). Much of our knowl-
edge about microglia biology currently relies on data obtained
from in vitro cultured cells. Under these conditions microglia
might however loose much of their uniqueness and turn into
prototype macrophages. This calls for the development of exper-
imental systems that will allow the study of microglia in their
unique physiological CNS environment.
Microglia are characterized by prominent expression of
the chemokine receptor CX3CR1. According to the current
chemokine nomenclature, which is based on the spacing of
N-terminal cysteines, the chemokine CX3CL1/fractalkine and
its sole receptor CX3CR1 constitute their own CX3C “fam-
ily” (Bazan et al., 1997; Imai et al., 1997; Pan et al., 1997).
CX3CR1 is a conventional Gαi-coupled seven-transmembrane
receptor. Its ligand CX3CL1 differs however from conventional
small peptide chemokines by the fact that it is synthesized as
a trans-membrane protein with the CX3C chemokine domain
displayed on an extended highly glycosylated, mucin-like stalk
(Bazan et al., 1997; Pan et al., 1997) (Figure 1A). To date, CX3CL1
shares this unique membrane anchorage only with one other
chemokine, the CXCR6 ligand CXCL16 (Matloubian et al., 2000).
Proteolytic cleavage of CX3CL1 by the disintegrin-like metallo-
proteinase ADAM10 results in constitutive release of different
sized shed CX3CL1 entities (Hundhausen et al., 2003). Moreover,
under inflammatory conditions, CX3CL1 shedding is also pro-
moted by ADAM17/TACE (Garton et al., 2001; Tsou et al.,
2001). Aside from the prominent expression in the mononu-
clear myeloid compartment (Jung et al., 2000), CX3CR1 receptor
expression has also been reported for an NK cell subset and cer-
tain T cell populations (Imai et al., 1997). Expression of the
ligand CX3CL1 outside the CNS has been reported for intestinal
epithelium and endothelium, potentially restricted to inflam-
matory settings (Muehlhoefer et al., 2000; Kim et al., 2011).
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FIGURE 1 | (A) Schematic of CX3C chemokine family and (B)
potential scenario of differential outcomes of neuronal shed and
membrane-anchored CX3CL1 engagement by microglia inducing or
suppressing microglial IL-1β production, respectively.
Although CX3CL1 and CX3CR1 are hence widely distributed
throughout the organism, their expression in given tissues is
often highly cell type-specific. This is particularly evident in the
CNS, where CX3CR1 expression is restricted to microglia and
CX3CL1 expression is confine to particular neurons (Nishiyori
et al., 1998; Hughes et al., 2002; Tarozzo et al., 2003). This is
best highlighted in CNS sections of double reporter animals,
that combine a CX3CR1gfp locus (Jung et al., 2000) with a BAC
transgene harboring a CX3CL1-promoter driven gene encoding a
red fluorescent cherry reporter (Figure 2) (Kim et al., 2011). In
CX3CL1cherry/CX3CR1gfp mice, mCherry+ neurons are NeuN+
DCX− mature neurons which are located in spatially specific
regions of the brain (Figure 2), with restricted expression in the
hippocampus, striatum and cortical layer II of the cerebral cor-
tex, as well as dorsal horn neurons in the spinal cord (Kim et al.,
2011). The exact nature and function of these CX3CL1-expressing
neurons remains to be deciphered.
SEEING IS BELIEVING—In situ VISUALIZATION OF
MICROGLIA USING CX3CR1gfp MICE
Microglial cells were originally identified in 1932 by the Cajal dis-
ciple del Rio-Hortega using silver staining and light microscopy.
However, unraveling the role of microglia in CNS had to
wait for the era of live brain imaging. Two seminal intravital
microscopy studies revealed that these presumably static ram-
ified cells are indeed highly dynamic and continuously extend
fine highly motile processes that allow them to survey their
immediate surrounding (Davalos et al., 2005; Nimmerjahn et al.,
2005). Moreover, in response to laser-mediated lesions, microglial
cells were found to rapidly respond to ATP released by astro-
cytes and redirected these processes toward the site of injury
(Davalos et al., 2005). These pioneering imaging studies took
advantage of CX3CR1gfp mice (Jung et al., 2000) that harbor a
targeted replacement of the CX3CR1 gene with a cDNA encod-
ing enhanced fluorescent protein and ever since have become
a popular research tool of the microglia research community.
Specifically, CX3CR1gfp mice have allowed researchers to inter-
rogate the microglia/neuron interface at unprecedented resolu-
tion complementing electron microscopy studies with critical
dynamic data (Tremblay et al., 2010). These studies revealed
that microglia are in intimate contact with neuronal synapses
and that these interactions are affected by visual experience
(Tremblay et al., 2010). Moreover, since the insertion of the
reporter gene in CX3CR1gfp mice generates a CX3CR1 null locus
(Jung et al., 2000) (Figure 3A), comparison of CX3CR1gfp/+
and CX3CR1gfp/gfp mice readily allows the probing for pheno-
types resulting from CX3CR1-deficiency using imaging strate-
gies (see below). Of note, a potential confounding problem is
the fact that when using CX3CR1gfp mice for microglia stud-
ies, animals are heterozygotes for the chemokine receptor and
microglia display due to the haplo-insufficiency considerable less
CX3CR1 surface expression (Jung et al., 2000). However, no
microglial phenotype has so far been reported for heterozygote
mutant CX3CR1gfp/+ animals, when compared tomice harboring
GFP transgene under the macrophage-specific ionized calcium-
binding adaptor molecule 1 (Iba1) promoter (Hirasawa et al.,
2005).
MICROGLIA AND THE CX3C AXIS
Analysis of receptor and ligand knock-out mice (Jung et al., 2000;
Cook et al., 2001; Combadiere et al., 2003) has revealed a number
of phenotypes resulting from the lack of CX3CR1/L1 interactions
outside the CNS, including effects on artherogenesis (Liu and
Jiang, 2011) and the ability of intestinal macrophages to sense gut
lumen content (Niess et al., 2005). The physiological role of the
CX3C axis and in particular mechanistic aspects, such as poten-
tial differential functions of the membrane-tethered and shed
CX3CL1 entities, remain incompletely understood.
Of note, the membrane-tethered CX3CL1molecule has a short
cytoplasmic tail lacking signaling motives. Moreover, CX3CL1 is
not known to associate with signaling competent co-receptors.
Hence, it remains unclear whether interactions of microglial
CX3CR1 and CX3CL1 expressed on the neuronal surface trig-
ger a direct response in neurons. Rather, functional outcomes
of CX3CL1 ligation with CX3CR1 seem to be restricted to the
microglial partner, and CX3CR1/L1 deficiencies seem to impinge
indirectly on neurons.
Below we will discuss the impacts of CX3CR1 and CX3CL1
deficiencies on microglia functions in CNS development, the
maintenance of CNS homeostasis and for the robustness of the
organism to handle pathological challenges.
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FIGURE 2 | Brain section of CX3CR1gfp:CX3CL1cherry double reporter animals
(Kim et al., 2011) highlighting CX3CR1-expressing microglia and subsets of
CX3CL1-expressing neurons in specific brain regions. Note that both
reporters are expressed in the cytoplasm and not as fusion proteins. Thus
they reflect the respective promoter activity but not the presence of the
respective proteins. Hence no co-localization has to be expected.
THE CX3C AXIS IN CNS DEVELOPMENT AND HOMEOSTASIS
Macrophages are long known to critically contribute to develop-
ment and the maintenance of homeostasis (Stefater et al., 2011).
The housekeeping functions of microglia are however only begin-
ning to be appreciated to their full extent (Tremblay et al., 2011).
As efficient phagocytes, microglia have emerged as key players in
postnatal synaptic pruning that trim excess connections estab-
lished in the developing brain for neuronal maturation. More
specifically, microglia were shown to engulf presynaptic inputs
during the pruning peak of retinal ganglion cells and the engulf-
ment was dependent upon neural activity and the microglia-
specific phagocytic signaling pathway involving complement
receptor 3 (CR3) (Schafer et al., 2012). Interestingly, this develop-
mental synaptic pruning by microglia seems affected in CX3CR1-
deficient mice, which reportedly display higher number of
immature dendritic spines, correlating with transiently reduced
microglia densities in their two first postnatal weeks (Paolicelli
et al., 2011). In the developing barrel cortex, CX3CR1-deficient
microglia enter the thalamocortical axon cluster to a lesser
degree, accompanied by delayed developmental switch of gluta-
mate receptor subunits—a hallmark of barrel cortex development
(Hoshiko et al., 2012). Here, microglia are thought to influence
the maturation of synapses in a non-phagocytic, and probably
soluble factor-mediated mechanism, which is yet to be eluci-
dated. However, it remains to be established, if late maturation is
directly mediated by the CX3C axis, or the effect seen results from
impaired entry of the cells to the barrel cortex. Other approaches,
such as conditional mutagenesis of microglial CX3CR1 will be
required to distinguish between these two scenarios.
Microglia also have been shown to shape adult hippocam-
pal neurogenesis through apoptosis-coupled phagocytosis (Sierra
et al., 2010). Again, the CX3CR1-deficiency seems to interfere
with this process, probably as a result of deleterious microglia
hyper-activation. Alongside reduced hippocampal neurogenesis,
CX3CR1−/− mice were thus reported to exhibit excessive IL-1β
expression and attenuated long term potentiation (LTP) resulting
in impaired cognitive functions (Bachstetter et al., 2011; Rogers
et al., 2011). However, others reported that CX3CR1−/− mice
have enhanced LTP and perform better in the cognitive tests,
but fail to improve these cognitive functions following exposure
to enriched environment, a known stimulator of neurogenesis
(Maggi et al., 2011). Interestingly, the seemingly contradicting
reports share the observation of reduced neuronal precursors in
neurogenic niches in the absence of CX3CR1, which may hint
at importance of CX3CL1 signaling for synaptic plasticity, rather
than basal synaptic activity. Further substantiating the immuno-
suppressive role of the CX3C axis, antibody-mediated blockade
of CX3CR1 in young adult rats induced IL-1β production and
decreased survival and proliferation of neural progenitor cells
(Bachstetter et al., 2011). Moreover, treatment with recombinant
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FIGURE 3 | (A) Schematic of modified CX3CR1 loci of CX3CR1gfp
mice (Jung et al., 2000) and (B) CX3CR1Cre and CX3CR1CreER mice
(Yona et al., 2013); (C) Efficient YFP labeling of both spinal cord
and brain microglia in CX3CR1CreER and CX3CR1Cre mice crossed
with R26-YFP reporter mice. CX3CR1CreER:R26-YFP mice were
treated with tamoxifen to induce the rearrangement (Yona et al.,
2013); (D) Induction but subsequent progressive loss of cells
harboring gene rearrangements in peripheral myeloid cells
(monocytes, intestinal macrophages) and persistence of genomic
modification in microglial cells.
CX3CL1 was found to reverse the age-related decrease in neuro-
genesis (Bachstetter et al., 2011).
THE CX3C AXIS AND PATHOLOGICAL SETTINGS
The CX3CR1 deficiency also effects neuro-inflammatory and
neurodegenerative diseases, as established in murine models of
Alzheimer’s and Parkinson’s disease (AD, PD) and amyothrophic
lateral sclerosis (ALS), as well as neuropathological conditions,
such as neuropathic pain and cerebral ischemia.
AD is characterized by the presence of extracellular amyloid-
β peptide (Aβ) deposits surrounded by activated glia and
dystrophic neurites. The CX3CR1-deficiency has been intro-
duced into several established murine AD models, includ-
ing the hTAu (Bhaskar et al., 2010), APP/PS1 (Fuhrmann
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et al., 2010; Lee et al., 2010), and CRND8 background (Liu
et al., 2010). Due to neuronal activation of the p38 MAPK
pathway, HTau transgenic CX3CR1−/− mice exhibit hyper-
phosphorylation of the tau protein, one of the AD hallmarks
(Bhaskar et al., 2010). Again this is probably the result of
excessive microglial IL-1β secretion (Bhaskar et al., 2010).
Interestingly though, in combination with APP/PS1 transgenes
the CX3CR1 deficiency reduced amyloid plaque aggregation
(Lee et al., 2010). Moreover, also the two-photon microscopic
comparison of APP:PS1:taup301L:Thy1-YFP:CX3CR1GFP/+ and
APP:PS1:taup301L:Thy1-YFP: CX3CR1gfp/gfp mice revealed that
the CX3CR1 deficiency was beneficent in that it resulted in
diminished microglia-mediated neuronal cell death, as well as
attenuated microglia migration velocity (Fuhrmann et al., 2010).
This suggests that microglia hyperactivation can have oppos-
ing outcomes in different models and potentially AD stages.
Crossing the CX3CR1−/− mice to CRND8 transgenic mice that
harbor a gene encoding a mutant human amyloid precursor
protein also resulted in reduced Aβ deposits, with the CX3CR1-
deficient microglia phagocytosing amyloid plaques and display-
ing higher proliferation rates in the plaque regions (Liu et al.,
2010). Interestingly, microglia treated in vitro with beta-amyloid
down-regulate CX3CR1 with concomitant induction of IL-6 and
TNF-α levels (Cho et al., 2011). Moreover, also in AD patients
both CX3CL1 and CX3CR1 are reportedly down-modulated (Cho
et al., 2011). In summary, disruption of the CX3C axis results in
microglia activation that includes beneficial enhanced phagocy-
tosis of amyloid plaques, but is also associated with potentially
detrimental secretion of pro-inflammatory cytokines causing
neurotoxicity.
In rodent models of LPS-induced neuroinflammation, PD
and ALS, CX3CR1-deficient microglia were found to overex-
press IL-1β and display neurotoxic activity (Cardona et al., 2006).
Moreover, in the intrastriatal 6-hydroxydopamine (6-OHDA)
rat model of PD administration CX3CL1 prevented dopamin-
ergic neuron death in the substantia nigra (Pabon et al., 2011).
The therapeutic potential of CX3CL1 regimens is further sup-
ported by the fact that exogenous CX3CR1 reduced ischemia-
induced cerebral infarct size, neurological deficits, and caspase-3
activation (Cipriani et al., 2011). Interestingly, in this study
CX3CL1-mediated neuroprotection required the adenosine sys-
tem. However of note, another group reported that lack of
CX3CR1 did not result microglial neurotoxicity, but rather sig-
nificantly reduces ischemic damage and inflammation, alongside
with reduced IL-1β and TNFα expression as well as smaller
infarcts (Denes et al., 2008). The reason for these discrepancies
remains unclear. Of note, the above-mentioned studies that evoke
therapeutic potential of CX3CL1 administration (Bachstetter
et al., 2011; Cipriani et al., 2011; Pabon et al., 2011) suggest that
the soluble, shed CX3CL1 isoform suffices to trigger CX3CR1 sig-
naling onmicroglia and suppress microglia activation. In support
of this notion, adenovirus-mediated gene therapy that selectively
expressed synthetic shed or non-sheddable CX3CL1 variants was
shown to ameliorate neurotoxicity when injected directly into the
substantia nigra of CX3CL1−/− mice that had been subjected to
a PD model initiated by MPTP neurotoxin challenge (Morganti
et al., 2012).
Challenging the notion of a mere anti-inflammatory role of
CX3CL1-induced CX3CR1 signaling, deficient CX3CR1 signal-
ing was reported to promote recovery after mouse spinal cord
injury (Donnelly et al., 2011). However, the effects observed in
this study might not be directly related to microglia but rather
linked to the concomitant impaired recruitment and activa-
tion of Ly6C− blood monocytes (Donnelly et al., 2011), which
depend on CX3CR1 signaling for survival (Landsman et al.,
2009). Nevertheless, the authors reported that in vitro exposure of
wt but not CX3CR1-deficient microglia induced their expression
of IL-6, though not IL-1β (Donnelly et al., 2011).
Microglia residing in the dorsal horn of the spinal cord
are critical contributors to nociceptive transmission following
peripheral nerve/tissue injury (Milligan and Watkins, 2009).
Shed neuronal CX3CL1 was proposed to be a critical medi-
ator of spinal neuronal-microglial communication in chronic
pain. CX3CL1 cleavage in the dorsal root ganglion (DRG) was
reported to depend on microglial release of the lysosomal pro-
tease cathepsin S potentially in response to ATP release and
P2X7 receptor (Clark et al., 2007, 2010). In keeping with the
notion that CX3CL1 is an ADAM substrate (Garton et al.,
2001; Tsou et al., 2001; Hundhausen et al., 2003), CX3CL1
could also be cleaved by the matrix metalloprotease MMP9 that
was found upregulated in injured DRG primary sensory neu-
rons (Kawasaki et al., 2008). Shed CX3CL1 was proposed to
engage microglial CX3CR1 and trigger via p38 MAPK phospho-
rylation pain-causing migroglial IL-1β secretion (Zhuang et al.,
2007). CX3CR1-deficient mice reportedly display unimpaired
responses to acute thermal and mechanical noxious stimuli, but
displayed deficits in inflammatory and neuropathic nociceptive
responses in the partial sciatic nerve ligation model (Staniland
et al., 2010). The CX3C axis also was reported to be involved in
the IL-1β-induced hyperalgesia observed in animals that have a
microglia-restricted reduction of the G protein-coupled recep-
tor kinase 2 (GRK2) (LysM-Cre:GRK2f/+ mice) (Willemen et al.,
2010).
One issue complicating the exact assessment of the impor-
tance of the CX3C axis for microglia function in pain perception
is that the involved anatomic sites include the spinal cord and
DRG that are part of the CNS and peripheral nerve system (PNS)
and are hence located behind and in front of the BBB, respec-
tively. Spinal cord and DRG are therefore differentially accessible
to the influx of monocytes and contribution of monocyte-derived
macrophages (see below).
The emerging recurrent theme of most of the studies address-
ing the role of the CX3C axis in microglia biology is that consti-
tutively expressed membrane-tethered neuronal CX3CL1 seems
to provide a tonic inhibitory signal to microglia that keeps these
cells in a quiescent “sampling” or surveillance mode (Biber et al.,
2007) (Figure 1B). Conversely, CX3CR1 and CX3CL1 deficien-
cies result in hyper-activated microglia, that depending on the
particular setting can be detrimental or beneficial to its environ-
ment. As opposed to the homeostatic role of trans-membrane
CX3CL1, under conditions of challenge such as pain-inducing
stimuli, CX3CL1 is shed from the neuronal surface and in
this context seems to trigger IL-1β production by microglia.
Differential activities of shed or membrane-tethered CX3CL1
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might be related to the recently reported requirement for integrin
binding for CX3CR1 signaling, although both isoforms interacted
with integrins (Fujita et al., 2012). Interestingly, shed, presumably
neuronal-derived CX3CL1 becomes detectable in serum, when
CX3CR1 is absent suggesting that CX3CR1-expressing cells pro-
vide a constitutive sink for it (Cardona et al., 2008). Clearly
though, further experimentation will be required to study poten-
tial differential effects of membrane-tethered and shed CX3CL1
entities on microglial CX3CR1 signaling in the in vivo context,
for instance involving animals manipulated to express exclusively
shed CX3CL1 (Kim et al., 2011).
THE CHALLENGE—MICROGLIA vs. MONOCYTE-DERIVED
MACROPHAGES
The high CX3CR1 expression in microglia and resulting bright
green fluorescence of CX3CR1gfp microglia turned CX3CR1gfp
mice into a valuable tool to probe microglia function. Moreover,
since circulating blood monocytes express CX3CR1, these
reporter animals became instrumental to solve a long-standing
debate about the origins of microglia cells. Microglia are
hematopoietic cells that develop independent of neuroectoderm-
derived neurons, astrocytes and oligodendrocytes. However,
the relationship microglia have with bone marrow-derived
macrophages that originate from blood monocytes had long
remained a matter of dispute. Irradiation chimeras were gen-
erated to define the hematopoietic stem cell (HSC) origin of
microglia. Yet, interpretation of the results obtained was con-
founded by the facts that first microglia are radio-resistant and
thus not replaced by a bone marrow graft, and that second the
irradiation compromised the BBB allowing monocyte infiltrates.
Revision of these studies taking advantage of CX3CR1gfp mice to
mark either the microglia or the blood compartment and intro-
ducing cellular exchange in parabionts and CCR2 dependency
as a indication of monocyte-derivation (Mildner et al., 2007;
Ajami et al., 2011) have now firmly established that microglia
and monocyte-derived brain macrophages are distinct entities.
Moreover, these studies were confirmed by fate mapping stud-
ies and the demonstration that amoeboid CX3CR1/GFP+ cells
seed the neuroepithelium of the developing brain well before
the emergence of “definitive” hematopoietic precursors, at E10.5–
E11.5, and following infiltration proliferate and change their
morphology into a more branched phenotype (Ginhoux et al.,
2010; Swinnen et al., 2013). As opposed to the macrophages
colonizing the surface ectoderm these early microglia lack
CCR2 expression, established using CX3CR1gfp:CCR2rfp dou-
ble reporter mice (Mizutani et al., 2012). Also the spinal cord
was shown to be colonized tissue as early as E10.5, although
the route by which the microglia precursors reach the respec-
tive tissues remain to be resolved (Rigato et al., 2011). The
emerging scheme thus holds that microglia are established from
primitive macrophages and subsequently maintain themselves
through longevity and limited self-renewal independent from
further input from definitive hematopoiesis through the HSC-
monocyte axis. This prenatally established, hard-wired resident
microglia compartment can be complemented on demand by
macrophages that arise frommonocytes recruited from the blood
circulation as a transient “emergency squad” during injury or
challenge (Mildner et al., 2009). Depending on the time and
route of their arrival to tissues, monocytes can contribute both
pro- and anti-inflammatory (Mildner et al., 2009; Shechter
et al., 2009), but seem eventually to be purged from the CNS
context after resolution of the inflammation (Ajami et al.,
2011).
Monocytic infiltrates pose a unique challenge to the study of
bona fide microglia, as monocyte-derived macrophages become
phenotypically indistinguishable from resident microglia, in par-
ticular upon activation of the latter. This is particularly evident
in the study of neuro-inflammatory disorders, such as the mul-
tiple sclerosis model of experimental autoimmune encephalitis
(EAE) that involves the BBB breakage and substantial mono-
cyte recruitment (Mildner et al., 2009). Emerging evidence from
mixed BM chimeras and parabionts indicates that functional
contributions of monocyte-derived cells differ from that of the
microglia (Ajami et al., 2011). However, efforts to address these
differential functions so far relied largely on the generation of
BM chimeras and the manipulation of BM-derived component.
Definitive evidence for microglia functions calls for experimental
systems that will allow the exclusive manipulation of microglia in
non-irradiated mice.
GENETIC MANIPULATION OF MICROGLIA IN
CONTEXT—CX3CR1Cre AND CX3CR1CreER ANIMALS
In order to overcome the above constraints of current microglia
studies, we decided to exploit the high CX3CR1 promoter activity
of microglial cells for their genetic manipulation. We generated
CX3CR1Cre and CX3CR1CreER animals (Yona et al., 2013), by
targeted insertion of the recombinase genes that mimicked the sit-
uation of the CX3CR1gfp locus previously shown to tightly reflect
endogenous CX3CR1 expression (Jung et al., 2000) (Figure 3B).
CX3CR1Cre mice express constitutively active Cre recombinase
resulting in the spontaneous non-reversible rearrangement of
loxP site-flanked alleles in CX3CR1-expressing cells. In contrast,
the CX3CR1CreER system comprises a conditional active Cre-
ERT2 recombinase that is fused to a mutated ligand-binding
domain (LBD) of the human estrogen receptor (ER) (Feil et al.,
2009). Two point mutations in the ER-LBD allow binding of
the synthetic estrogen antagonist tamoxifen (TAM) and prevents
constitutive activation of the CreER by endogenous estradiol (Feil
et al., 2009). In the unbound form, the CreER fusion protein
resides in the cytoplasm in an inactive complex with heat shock
proteins. Upon administration and binding of TAM, the CreER
is freed to translocate to the nucleus and mediate the site-specific
recombination.
Importantly, CX3CR1Cre and CX3CR1CreER animals differ
considerably with respect to the cells targeted. In CX3CR1CreER
animals only cells that express CX3CR1 and hence the CreER
transgene will undergo rearrangement at the time of the TAM
treatment. In contrast and as best demonstrated in combina-
tion with respective reporter mouse strains (Yona et al., 2013),
in CX3CR1Cre animals also cells that are derived from CX3CR1+
cells but subsequently silenced CX3CR1 expression will have
recombined the loxP-flanked loci. CX3CR1Cre animals therefore
report on the history of the cell and can be used for fate mapping
studies (Yona et al., 2013).
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Analysis of CX3CR1Cre and CX3CR1CreER mice crossed to
animals harboring a floxed YFP reporter gene (Srinivas et al.,
2001) established that these systems indeed efficiently target CNS
microglia (Yona et al., 2013). As expected, in CX3CR1Cre: YFP
mice, and only in TAM-treated CX3CR1CreER: YFP mice, more
than 95% of both brain and spinal cord microglia were found
YFP labeled (Figure 3C). Thus, when crossed to mice harboring
“floxed” candidate genes, these systems can be utilized to delete or
express specific genes in CX3CR1+ microglia, either straight from
their development onwards, using the constitutive Cre system, or
in specific time windows, using the inducible Cre system.
Of note, certain lymphocyte subsets and myeloid cells, other
than microglia express CX3CR1. TAM treatment of CX3CR1CreER
mice results accordingly also in gene rearrangement in these cells
(Yona et al., 2013) (Figure 3D), includingmonocytes and periph-
eral macrophages, i.e., exactly the cells that have confounded the
functional analysis of the microglia compartment in the previous
studies. However, most peripheral myeloid cells that underwent
Cre activation and rearrangements have a limited half-life and
are hence continuously replaced by BM-derived cells. Genetic
modifications, such as the activation of the YFP reporter gene
or the deletion of “floxed” alleles are thus progressively lost with
time in these populations. In contrast, the resident microglia pool
which self-renews without further input from the BM retains
once introduced gene modifications throughout the life of the
organism (Figure 3D). This feature thus allows generation of
animals that harbor specific genetic manipulations restricted to
microglia. Of note, there are also other tissue macrophage pop-
ulations such as Kupffer cells and peritoneal macrophages that
are established before birth and then self renew (Schulz et al.,
2012; Yona et al., 2013). However, as most of these cells lack
CX3CR1 expression, they are not targeted by the CX3CR1CreER
approach in adulthood (Yona et al., 2013). CX3CR1+ intesti-
nal macrophages on the other hand loose their gene modifica-
tions, as they are progressively replaced by monocytes (Zigmond
et al., 2012) (Figure 3D). Taken together, the combination of
CX3CR1Cre and CX3CR1CreER animals provides a unique tool
to probe for the involvement of microglia in CNS develop-
ment, CNS maintenance and CNS responses to pathological
challenges.
CONCLUSION
Microglia are the main representatives of the immune system
in the healthy brain as such likely to critically contribute to the
brain’s resistance to pathological challenges. Moreover, recent
data highlight the critical involvement of microglia in CNS devel-
opment and homeostasis. Given its strategic localization at the
neuronal/microglial interface the CX3C axis is likely to play a
prominent role in these activities. Thus accumulating evidence
suggest that neuronal CX3CL1 acts as a critical inhibitory signal
retaining microglia in quiescent mode and preventing collateral
damage due to microglia hyper-activation. Aside from its biolog-
ical role, the CX3CR1 chemokine receptor provides us however
also with a unique foothold to study microglia in context using
state of the art imaging and gene manipulation approaches. The
near future is hence likely to provide valuable insight into con-
tributions of these intriguing cells to brain physiology and might
pave the way for the development of microglia manipulation for
therapeutic purposes.
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